on VALNEVA (EPA:VLA)
Valneva appoints Dr Hanneke Schuitemaker as Scientific Director
Saint-Herblain (France), May 21, 2024 – Valneva SE, a company specializing in vaccines, has appointed Dr Hanneke Schuitemaker as Scientific Director and member of the Executive Committee from June 3, 2024.
Dr. Schuitemaker, with over twenty years of experience, will focus on accelerating Valneva's preclinical and translational R&D activities. She previously served as Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson.
Thomas Lingelbach, CEO of Valneva, expressed his enthusiasm for the appointment, emphasizing the importance of innovation in the company's strategy. Dr. Schuitemaker also expressed his excitement about joining Valneva.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALNEVA news